Search results

durvalumab (Imfinzi)

Durvalumab in combination with etoposide and either carboplatin or cisplatin for the first-line treatment of adults with extensive-stage small cell lung cancer.

durvalumab (Imfinzi)

In combination with platinum-based chemotherapy as neoadjuvant treatment, followed by durvalumab as monotherapy after surgery, is indicated for the treatment of adults with resectable (tumours ≥ 4 cm and/or node-positive) NSCLC and no known EGFR mutations or ALK rearrangements.

durvalumab (Imfinzi)

In combination with carboplatin and paclitaxel for the first-line treatment of adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy, followed by maintenance treatment with: durvalumab as monotherapy in endometrial cancer that is mismatch repair deficient (dMMR) durvalumab in combination with olaparib in endometrial cancer that ismismatch repair proficient (pMMR).

durvalumab (Imfinzi)

in combination with etoposide and either carboplatin or cisplatin is indicated for the first-line treatment of adults with extensive-stage small cell lung cancer (ES-SCLC).

durvalumab (Imfinzi)

as monotherapy for the treatment of locally advanced, unresectable non-small cell lung cancer (NSCLC) in adults whose tumours express programmed cell death ligand 1 (PD-L1) on ≥1% of tumour cells (TCs) and whose disease has not progressed following platinum-based chemoradiation therapy (CRT)

durvalumab (Imfinzi)

In combination with gemcitabine and cisplatin for the first-line treatment of adults with locally advanced, unresectable, or metastatic biliary tract cancer (BTC).

durvalumab (Imfinzi)

In combination with tremelimumab for the first line treatment of adults with advanced or unresectable hepatocellular carcinoma.

durvalumab (Imfinzi)

Treatment of adults with limited-stage small-cell lung cancer (LS-SCLC) whose disease has not progressed following platinum-based chemoradiation therapy (CRT).

December 2024 decisions news release

June 2025 decisions news release

June 2019 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly licensed medicines for use by NHSScotland, has today (Monday 10 June) published advice accepting five new medicines.

November 2023 decisions news release

The Scottish Medicines Consortium (SMC), which advises on newly-licensed medicines for use by NHSScotland, has today (Monday, November 13) published advice on 9 medicines.

February 2025 decisions news release